OOIR: Observatory of International Research

Papers

(The H4-Index of Headache is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Pilot study evaluating treatment with sumatriptan for moderate to severe post‐traumatic headache: A phase 2 open‐label study	178
Migraine treatment in pregnancy: A survey of comfort and treatment practices of women's healthcare providers	86
Virtual issue: Education in headache medicine: Insights and advancements from 2023 to 2024	65
Identifying cognitive‐affective mechanisms underlying disability in episodic migraine: Using the fear avoidance model to examine interactions	63
Evidence for increased background neural noise in migraine with aura: Hyperactive but not hyperresponsive	52
Assessing the influence of migraine on ischemic penumbra and on the prognosis of ischemic stroke: A prospective cohort study	48
Erratum	46
Characteristics associated with response to subcutaneously administered anti‐CGRP monoclonal antibody medications in a real‐world community cohort of persons living with migraine: A retrospective clin	44
Facial variant of epicrania fugax secondary to a cerebellopontine angle meningioma	44
Drug‐resistant epicrania fugax: Responding to onabotulinumtoxinA	42
Temporary occipital nerve stimulation as transitional therapy for chronic intractable cluster headache: A case report and proof of concept	39
Response to Letter to the Editor regarding “Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked	38
Migraine screening in English and Spanish	37
Migraine and peripheral pain models show differential alterations in neuronal complexity	36
Normal glymphatic system function in patients with new daily persistent headache using diffusion tensor image analysis along the perivascular space	35
Effectiveness and acceptability of oral migraine preventives: A prospective, observational study	34
Cortical synchronization of spontaneous trigeminal neuropathic pain monitored with in vivo optical imaging of calcium activity in freely moving mice	31
Anxiety, depression, and headache‐related disability in a large pediatric clinic–based sample	30
A retrospective analysis of the use of candesartan for migraine prevention in adolescents	29
Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine	28
Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment	28
Long‐term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis	28
The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine	28
A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine	28
Routine migraine screening as a standard of care for Women's health: A position statement from the American Headache Society	27

Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study	27
Headache and psychological variables as predictors of disability in individuals with primary headache disorders	27